|1.||Oka, Michiko: 9 articles (09/2013 - 08/2007)|
|2.||Tanaka, Mitsushi: 6 articles (07/2012 - 08/2007)|
|3.||Oyama, Tatsuya: 4 articles (09/2013 - 07/2009)|
|4.||Kakehi, Yoshiyuki: 3 articles (03/2014 - 03/2011)|
|5.||Sugimoto, Mikio: 3 articles (03/2014 - 03/2011)|
|6.||Matsumoto, Seiji: 3 articles (09/2013 - 04/2008)|
|7.||Ueda, Makoto: 3 articles (09/2009 - 07/2009)|
|8.||Xia, Zhang: 2 articles (03/2014 - 06/2011)|
|9.||Kyotani, Junko: 2 articles (09/2013 - 09/2009)|
|10.||Yamada, Shizuo: 2 articles (03/2013 - 07/2012)|
04/01/2008 - "The present findings raise the possibility that eviprostat could be an effective treatment for bladder overactivity associated with inflammation."
01/01/1995 - "Histologically, preoperative administration of Eviprostat improved the degree of prostatic inflammation. "
03/01/2014 - "Eviprostat suppresses the stromal proliferation and inflammation in the rat prostate after the establishment of NBP at least partly owing to inhibitory effect on CCL2/MCP-1 production in the prostate."
09/01/2013 - "Eviprostat-mediated suppression of increased bladder oxidative stress and inflammation caused by bladder OE may contribute to the improvement of BBF and bladder function by Eviprostat."
09/15/2009 - "These activities of Eviprostat may also contribute to the amelioration of prostate inflammation in BPH patients. "
05/01/2008 - "With supplemental administration of Eviprostat, significant improvement was observed in the symptoms of incomplete emptying, daytime frequency, intermittency, weak stream, total IPSS, sum of the IPSS subscores for voiding symptoms (intermittency, weak stream and straining), sum of the IPSS subscores for storage symptoms (daytime frequency, urgency and nocturia), and QOL score. "
04/01/2009 - "Significant improvements were observed in the incomplete emptying and frequency scores from the day after the start of administration, in the intermittence and straining scores from day 2, in the urgency and weak stream scores from day 3 and in the nocturia score from day 5. The QOL index significantly improved on day 7. In comparison with Eviprostat, Tamsulosin showed a stronger improvement tendency in the total IPSS, voiding symptoms score and incomplete emptying score and the difference was significant. "
|3.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
09/01/2005 - "To study the efficacy and safety of Eviprostat for the treatment of benign prostatic hyperplasia (BPH). "
09/01/2005 - "[Clinical study of Eviprostat for the treatment of benign prostatic hyperplasia]."
09/01/2013 - "We investigate the effect of the phytotherapeutic agent Eviprostat, a treatment for benign prostatic hyperplasia (BPH) that has antioxidant and anti-inflammatory activity, on urinary bladder blood flow (BBF), and function in a rat model of bladder overdistension and emptying (OE). "
01/01/2012 - "Eviprostat is an anti-oxidant, anti-inflammatory phytotherapeutic agent that is commonly used to treat lower urinary tract symptoms (LUTS) in benign prostatic hyperplasia in Japan and Germany. "
02/01/2010 - "Eviprostat is a phytotherapeutic agent that has been used widely for more than 40 years in the treatment of benign prostatic hyperplasia (BPH) in Japan and Germany, and is known to have antioxidant activity. "
03/01/2013 - "Therefore, Eviprostat may be a pharmacologically useful phytotherapeutic agent for cystitis."
04/01/2008 - "Effect of eviprostat on bladder overactivity in an experimental cystitis rat model."
03/01/2013 - "Repeat Eviprostat treatment significantly improved detrusor overactivity, down-regulated the expression of bladder pharmacological receptors and increased urinary cytokine levels in rats with cyclophosphamide induced cystitis. "
04/01/2008 - "The purpose of this study was to investigate the effects of eviprostat, a phytotherapeutic drug, on bladder overactivity and inflammation in a cyclophosphamide (CYP)-induced cystitis rat model. "
01/01/2015 - "A phytotherapeutic agent, Eviprostat, is reportedly effective in a rat model of nonbacterial prostatitis. "
06/01/2011 - "The up-regulation of the Mic1 gene observed in prostatitis control rat prostates was significantly suppressed in prostatitis Eviprostat rats (P < .0001). "
06/01/2011 - "The high levels of macrophage infiltration found in prostatitis control rats were significantly reduced in prostatitis Eviprostat rats (P < .0001). "
06/01/2011 - "The mean S/E ratio in prostatitis Eviprostat rats was significantly lower than in prostatitis control rats (P < .0001). "
06/01/2011 - "Ten-month old Wistar rats were divided into 4 groups of 10: (1) NBP non-mixed feed (prostatitis control group); (2) NBP Eviprostat (0.1%) mixed feed (prostatitis Eviprostat group); (3) non-NBP non-mixed feed (nonprostatitis control group); and (4) non-NBP Eviprostat mixed-feed (nonprostatitis Eviprostat group). "
|2.||Adrenergic alpha-1 Receptor Antagonists
|8.||Biological Markers (Surrogate Marker)
|10.||Reactive Oxygen Species (Oxygen Radicals)
|1.||Phytotherapy (Herbal Therapy)
|2.||Prostatectomy (Retropubic Prostatectomy)